Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Cyanine3

Product Details

Size	1 mg
Species Reactivity	Mouse
Host/Isotype	Goat / IgG
Class	Polyclonal
Туре	Secondary Antibody
Conjugate	Cyanine3
Excitation/Emission Max	554/566 nm
Immunogen	Gamma Immunoglobins Heavy and Light chains
Form	Liquid
Concentration	2 mg/mL
Purification	purified
Storage buffer	PBS, pH 7.5
Contains	5mM sodium azide
Storage conditions	4° C, store in dark
RRID	AB_2534030

Applications	Tested Dilution	Publications
Western Blot (WB)	1:10,000	-
Immunohistochemistry (IHC)	-	0 Publication
Immunohistochemistry (Frozen) (IHC (F))	-	0 Publication
Immunocytochemistry (ICC/IF)	1-10 μg/mL	0 Publication
Flow Cytometry (Flow)	1-10 μg/mL	-
Miscellaneous PubMed (Misc)	-	0 Publication

1

Product Images For Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Cyanine3



Mouse IqG (H+L) Cross-Adsorbed Secondary Antibody (A10521) in ICC/IF Immunofluorescence analysis of Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Cyanine3 (Product # A10521) was performed using SH-SY5Y (positive model) and T-47D (negative model) cells stained with Nestin Monoclonal Antibody (10C2), eBioscience™ (Product # 14-9843-80). The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton[™] X-100 for 10 minutes, blocked with 1% BSA for 1 hour and labeled with 2 µg/mL primary antibody for 3 hours at room temperature. Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Cyanine3 (Product # A-10521, 1: 2000 dilution) in 0.1% BSA in PBS for 45 minutes at room temperature, was used for detection of Nestin in the cytoskeleton (Panel a: Red). Nuclei (Panel b: blue) were stained with Hoechst33342 (Product # H1399). F-actin was stained with Alexa Fluor® 488 Phalloidin (Product # A12379, 1:300) (Panel c: green). Panel d represents the composite image. The specificity of the secondary antibody was proved by the absence of signal in T-47D (negative model for Nestin) due to no primary antibody binding (Panel e). Non-specific staining was not observed with secondary antibody alone (panel f). The images were captured at 40X magnification in CellInsight CX7 LZR High-Content Screening (HCS) Platform (Product # CX7A1110LZR) and externally deconvoluted (D.Sage et al./Methods 115 (2017) 28-41).

Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody (A10521) in ICC/IF



Blue = Nucleus, Orange = VE-cadherin

Role of S1P and S1PRs in EC barrier destabilization induced by LPS and cytokines. (A) Immunofluorescence staining of VE-cadherin and Western blot analysis of VE-cadherin and GAPDH in EA.hy926 and HUVEC after stimulation with LPS and cytokines or vehicle. Representative images from one out of three individual experiments are shown, size bar = 50 μ m. (B) Western blot quantification (top) and representative Western blot (bottom) of VE-cadherin expression in EA.hy926 and HUVEC after stimulation with LPS and cytokines or vehicle, means ± SEM, n = 3, * p < 0.05, determined by two-sided Student's ttest. (C) Resistance following treatment with a mix of LPS and cytokines (50 ng /mL IL1, 50 ng/mL TNF, 1 µg/mL LPS), and re-stimulated with 1 µM of the S1PR1 agonist CYM5442, 1 µM of the S1PR1,3,4,5 agonist FTY720-phosphate and its non-phosphorylated precursor FTY720, and 1 µM S1P. Line plots represent one experiment out of three with black arrows indicating the addition of stimuli at the corresponding time points. The dark grey line represents an unstimulated control, the light grey line represents a control stimulated with LPS and cytokines without second stimulation. Bar graph represents means ± SEM, n = 3, ** p < 0.01, *** p < 0.001, determined by two-sided Student's t-test. Normalized resistance values were taken before (controls) and after treatment with S1P, FTY720-P... Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32290092), licensed under a CC BY license.



Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody (A10521) in ICC/IF

Dependence and reversibility of EC barrier stability in HUVEC and EA.hy926. (A) Resistance following treatment with 3 μ M S1PR1 antagonist W146 or 120 μ g/mL of anti-S1P antibody Sphingomab, followed by the removal of the added substances. Line plot represents one experiment out of three with black arrows indicating the addition and removal of W146 or Sphingomab at the corresponding time points. (B) Immunofluorescence staining of VE-cadherin in HUVEC after addition of 3 μ M S1PR1 antagonist W146, followed by removal of the added substance. Representative images from one out of three individual experiments are shown. Pictures were taken 6 h after addition of W146 and 12 h following removal of W146. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32290092), licensed under a CC BY license.

View more figures on thermofisher.com

2

□ 193 References

Dual action of macrophage miR-204 confines cyclosporine A-induced atherosclerosis. Br J Pharmacol (2024)

Murine Model of Airway Fibrosis has Anatomic, Physiologic, and Molecular Congruency to Human iSGS. Otolaryngol Head Neck Surg (2024)

Biophysical properties of NaV1.5 channels from atrial-like and ventricular-like cardiomyocytes derived from human induced pluripotent stem cells. Sci Rep (2023)

CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction Research Square (2023)

Cardiac involvement in patient-specific induced pluripotent stem cells of myotonic dystrophy type 1: unveiling the impact of voltage-gated sodium channels. Front Physiol (2023)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by property trained individuals. Unless otherwise stated in the Documentation, this warranty is marring packing are from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty are or other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample furnished. To EVENT the WARRANTES IS CHARNED, INCE DEVENT TO INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULTS DURING THE WARRANT TES NO ENDITICES DURING THE WARRANT TES NO ENDITICES DURING THE WARRANT THERE IS NO BULGATION TO REPEAR. REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS DURING THE WARRANT THERE IS NO BULGATION TO REPLAR. REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS DURING THE WARRANT TES NO BULGATION TO REPLAR. REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS DURING THE WARRANT THE WARRANT THE NO LOCATION TO REPLAR. REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS SOLE OPTION. THERE IS NO BULGATION TO REPLAR. REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. UNless otherwise expressly stated on the Product or in the documentation accompanying the Product is intended for research only an